secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001140361-24-025173
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q1 revenue $81.9M (+44% YoY); raises FY2024-25 guidance
----------------------------------------------------------------------

- GAAP net income $17.8M vs net loss of $6.8M in prior year; adjusted EBITDA $26.4M, a 970% increase.
- Gross margin improved to 48% from 29% YoY; working capital $223.3M, cash $45.3M.
- FY2024 revenue guidance raised to >$355M (prior >$330M); net income >$85M (prior >$65M).
- FY2025 revenue guidance raised to >$410M; adjusted EBITDA >$160M, up from >$140M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124025173/0001140361-24-025173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124025173/ef20028782_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-025173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer